Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset
Delveinsight
FEBRUARY 23, 2021
Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed, and existing investor Delos Capital.
Let's personalize your content